Tue, October 24, 2017
Mon, October 23, 2017
Fri, October 20, 2017

Andrew Berens Maintained (BPMC) at Buy with Increased Target to $78 on, Oct 23rd, 2017

Andrew Berens of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $45 to $78 on, Oct 23rd, 2017.

Andrew has made no other calls on BPMC in the last 4 months.



There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, 0 agree with Andrew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Andrew


  • Arlinda Lee of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $66 on, Wednesday, September 20th, 2017